NASDAQ$LNTH
Lantheus Holdings, Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Lantheus reported Q3 2025 total revenues of $384.0M with net income of $27.8M and diluted EPS of $0.41.
PYLARIFY and precision diagnostics drove total revenues of $384.0 million, up from $378.7 million a year ago. Net income was $27.8 million with diluted EPS of $0.41 as radiopharmaceutical oncology demand remained strong.
- Q3 total revenues $384.0M.
- Net income $27.8M; diluted EPS $0.41.
- PYLARIFY and DEFINITY anchor product mix.
- Strategic partnerships and CDMO revenue supplement growth.
Headline financials
Revenue & EPS history
Lantheus · Revenue · Quarterly
$384M
Revenue by segment
Lantheus · $76.9M total across 2 segments · Q3 2020
- DEFINITY$55.4M—72.1%
- TechneLite$21.5M—27.9%
Forward guidance
The filing discusses Lantheus Holdings's outlook, capital priorities, and key risks, including guidance or operating targets where disclosed.
Tailwinds
- Lantheus Holdings cites execution and demand supporting the near-term outlook.
- Balance sheet and capital allocation remain focal points in the filing.
Headwinds
- Macro, competition, and input costs may pressure margins quarter to quarter.
- One-time items and segment mix can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+4.2%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+10.2%
Avg return
30 days after
51%
23 / 45 earnings
Positive
+63.0%
Q2 2016
Best reaction
-23.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.6% | +11.7% | +17.2% | |
| Q4 2025 | -0.4% | +4.1% | -1.7% | |
| Q3 2025 | -6.2% | -6.7% | +10.6% | |
| Q1 2025 | -23.1% | -24.2% | -22.2% | |
| Q4 2024 | +16.5% | +18.5% | +20.1% | |
| Q3 2024 | -23.2% | -26.9% | -22.6% | |
| Q2 2024 | -10.2% | -9.8% | -3.0% | |
| Q1 2024 | +12.1% | +12.8% | +21.4% | |
| Q4 2023 | +16.9% | +20.4% | +4.1% | |
| Q3 2023 | -2.7% | -1.6% | +11.7% | |
| Q2 2023 | -7.5% | -13.9% | -17.7% | |
| Q1 2023 | +14.0% | +17.9% | +7.5% | |
| Q4 2022 | +24.3% | +27.0% | +39.8% | |
| Q3 2022 | -12.0% | -17.2% | -11.1% | |
| Q2 2022 | +3.5% | +5.1% | +3.4% | |
| Q1 2022 | +11.6% | +12.7% | +19.0% | |
| Q4 2021 | +61.6% | +70.3% | +72.9% | |
| Q3 2021 | +16.6% | +21.5% | +6.9% | |
| Q2 2021 | +7.5% | +6.5% | +2.1% | |
| Q1 2021 | -5.7% | -7.2% | +3.7% | |
| Q4 2020 | -5.0% | -6.9% | +0.7% | |
| Q3 2020 | +0.3% | +7.6% | +22.2% | |
| Q2 2020 | -14.2% | -19.4% | -14.1% | |
| Q1 2020 | -14.0% | -9.4% | -2.1% | |
| Q4 2019 | +1.2% | -3.5% | -21.7% | |
| Q3 2019 | +4.1% | +6.4% | +4.9% | |
| Q2 2019 | -21.3% | -19.9% | -24.2% | |
| Q1 2019 | -5.1% | +3.8% | -1.0% | |
| Q4 2018 | +18.8% | +29.1% | +35.4% | |
| Q3 2018 | +10.2% | +18.8% | +40.8% | |
| Q2 2018 | -7.6% | -6.6% | +11.4% | |
| Q1 2018 | -2.5% | -14.7% | -20.4% | |
| Q4 2017 | -22.5% | -17.2% | -21.0% | |
| Q3 2017 | +19.3% | +17.9% | +16.8% | |
| Q2 2017 | -16.0% | -6.8% | -5.1% | |
| Q1 2017 | +13.1% | +1.5% | +25.0% | |
| Q4 2016 | +28.6% | +33.9% | +25.9% | |
| Q3 2016 | +9.8% | +1.7% | +6.4% | |
| Q2 2016 | +63.0% | +63.9% | +155.4% | |
| Q1 2016 | -6.2% | — | — | |
| Q1 2015 | -6.2% | — | — | |
| Q4 2015 | +17.1% | — | — | |
| Q3 2015 | +27.6% | — | — | |
| Q4 2014 | -1.3% | — | — | |
| Q2 2015 | -1.3% | — | — | |
| Q2 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro